Sun Pharma's Noveltreat Gets DCGI Approval for Weight Loss

Sun Pharmaceutical Industries has announced it has received approval from the Drugs Controller General of India (DCGI) for Noveltreat, a generic version of semaglutide injection.

This licence paves the way to a new, low-priced alternative in weight management therapy of the Indian patients. The Noveltreat also aims at helping individuals with obesity and associated cases to lose weight.

Novo Nordisk originally developed semaglutide but it has caught the interest of people all over the world due to its great ability to assist people in losing weight. At Noveltreat, Sun Pharma is trying to offer an alternative to the branded version of the product at a lower price without compromising benefits. The mechanism of action of the drug is that it mimics a hormone that assists in the regulation of blood sugar and appetite making the user easy to control their weight.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

Noveltreat by Sun Pharma will be offered in pre-filled and injected in a pen, which is easy to administer at home. The firm believes in enhancing access to affordable healthcare and it hopes to have a drastic effect in the rising obesity issue in India.

Sun Pharma’s Noveltreat will be available in a pre-filled pen for self-injection, making it convenient for patients to use at home. The company is committed to improving access to affordable healthcare and hopes to make a significant impact on the growing obesity crisis in India.

“We are pleased to receive approval for Noveltreat, which will provide patients with a proven treatment for weight management,” said a company spokesperson. With the approval in place, Sun Pharma is now preparing for the launch of Noveltreat, offering a promising new solution to those looking to manage their weight more effectively.